Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 3/20 | 0.38 |
| ▸ | PPARA | Q07869 | 3/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5486813 | 1.00 | APP (0.44) | APPCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL5507858 | 0.79 | APP (0.61) | APPCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL5507856 | 0.79 | APP (0.61) | APPCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL9146168 | 0.79 | APP (0.61) | APPCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL5480351 | 0.79 | APP (0.44) | APPCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL5487427 | 0.79 | APP (0.44) | APPCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL5483934 | 0.79 | APP (0.44) | APPCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7386833 | 0.79 | APP (0.44) | APPCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL5480347 | 0.79 | APP (0.44) | APPCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL5487421 | 0.79 | APP (0.44) | APPCYP1A2CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202213-B2 | Combination therapy using a dual PPAR-α/PPAR-γ activator and a GLP-1 derivative for the treatment of metabolic syndrome and related diseases and disorders | NOVO NORDISK A/S (DK) | 2007-04-10 | — | — | US | disclosed |
| US-20030199451-A1 | Combination therapy using a dual PPAR-a/PPAR-y activator and a GLP-1 derivative for the treatment of metabolic syndrome and related diseases and disorders | HIGH POINT PHARMACEUTICALS, LLC | 2003-10-23 | — | — | US | disclosed |
| US-6569901-B2 | (E)-(S)-2-Ethoxy-3-(4-(5-phenyl-pent-2-en-4-ynyloxy)-phenyl)-propionic acid, ethyl ester for example; treating conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR); diabetes, obesity | NOVO NORDISK A/S (DK) | 2003-05-27 | — | — | US | disclosed |
| EP-1254102-A1 | ALKYNYLSUBSTITUTED PROPIONIC ACID DERIVATIVES AND THEIR USE AGAINST DIABETES AND OBESITY | Novo Nordisk A/S (DK) | 2002-11-06 | — | — | EP | disclosed |
| US-20010041709-A1 | New compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC | 2001-11-15 | — | — | US | disclosed |
| WO-2001055086-A1 | ALKYNYLSUBSTITUTED PROPIONIC ACID DERIVATIVES AND THEIR USE AGAINST DIABETES AND OBESITY | NOVO NORDISK A/S (DK) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041709-A1 | New compounds, their preparation and use | PPARG, PPARD, PPARA | APP 3370/4885CYP1A2 279/4885CYP3A4 592/4885 |
| US-20030199451-A1 | Combination therapy using a dual PPAR-a/PPAR-y activator and a GLP-1 derivative for the treatment of metabolic syndrome and related diseases and disorders | GLP1R, PPARG, PPARA | APP 1722/4885CYP1A2 647/4885CYP3A4 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.